American Vanguard (AVD)
NYSE:AVD
Top Page
American Vanguard
(NYSE:AVD)
Select Model
Select Model
Rating:43Neutral
Price Target:
$2.00
▼(-47.23% Downside)
Action:ReiteratedDate:03/21/26
The score is held down primarily by weakened financial performance (recent losses, higher leverage, and negative free cash flow) and a strongly bearish technical setup with the stock far below key moving averages. The latest earnings call provides a partial offset via improved EBITDA, cost controls, and maintained EBITDA guidance, but valuation support is limited given the negative P/E and no dividend data.
Positive Factors
Improving adjusted EBITDA & margins
A multi-fold rise in adjusted EBITDA and 300bp gross margin improvement reflect durable operating leverage from cost controls and manufacturing optimization. Sustained margin recovery can convert to stronger cash flow and resilience against commodity-driven revenue swings over the next 2–6 months.
Negative Factors
Declining revenue trend
A multi-year top-line decline erodes scale, reduces fixed-cost absorption and bargaining power with suppliers and channels. Without clear and sustained volume or product-mix improvements, lower revenue constrains margin recovery and the company's ability to rebuild resilient cash flows.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving adjusted EBITDA & margins
A multi-fold rise in adjusted EBITDA and 300bp gross margin improvement reflect durable operating leverage from cost controls and manufacturing optimization. Sustained margin recovery can convert to stronger cash flow and resilience against commodity-driven revenue swings over the next 2–6 months.
Read all positive factors
American Vanguard (AVD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$68.78M
Dividend YieldN/A
Average Volume (3M)196.68K
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue Growth-4.29%
EPS Growth-276.74%
CountryUS
Employees845
SectorBasic Materials
Sector Strength58
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)-0.99
Shares Outstanding28,539,562
10 Day Avg. Volume247,772
30 Day Avg. Volume196,681
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.56
Price to Sales (P/S)0.21
P/FCF Ratio-32.36
Enterprise Value/Market Cap3.62
Enterprise Value/Revenue0.48
Enterprise Value/Gross Profit1.72
Enterprise Value/Ebitda14.95
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.38
Revenue Forecast (FY)$555.00M
American Vanguard Business Overview & Revenue Model
Company Description
American Vanguard Corporation, through its subsidiaries, develops, manufactures, and markets specialty chemicals for agricultural, commercial, and consumer uses in the United States and internationally. It manufactures and formulates chemicals, in...
How the Company Makes Money
American Vanguard makes money primarily by selling crop protection and pest control products. Revenue is generated from (1) sales of formulated products (finished, branded or labeled pesticides and pest management solutions) to distributors, retai...
American Vanguard Earnings Call Summary
Earnings Call Date:Nov 10, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The earnings call reflected a positive sentiment overall, with significant improvements in EBITDA, gross margins, and cost management. While there were challenges in international markets and trade tensions with China, the company's cost control measures and strong performance in the U.S. crop segment offset these issues.Positive Updates
Significant EBITDA Growth
Adjusted EBITDA increased from $1.8 million in the previous year to $8.2 million in the current quarter, marking an increase of more than 350%.
Negative Updates
Lowered Net Sales Forecast
Net sales forecast for 2025 was lowered to $520 million to $535 million due to various market conditions, particularly in Mexico, Central America, and Australia.
Read all updates
Q3-2025 Updates
Positive
Negative
Significant EBITDA Growth
Adjusted EBITDA increased from $1.8 million in the previous year to $8.2 million in the current quarter, marking an increase of more than 350%.
Read all positive updates
Company Guidance
During the American Vanguard Third Quarter 2025 Earnings Conference Call, CEO Dak Kaye highlighted a significant improvement in financial performance, with adjusted EBITDA rising from $1.8 million in the prior year to $8.2 million in the current quarter, an increase of over 350%. Gross profit margins improved by 300 basis points, largely due to optimized manufacturing efforts and cost control measures. Operating expenses were reduced by approximately $6 million compared to Q3 2024, and net trade working capital decreased by $24 million year-over-year. The company's net debt stands at $165 million, showing a modest reduction of $2 million from the previous year. Looking ahead, American Vanguard maintains its full-year 2025 adjusted EBITDA target of $40 million to $44 million, despite lowering its net sales forecast to $520 million to $535 million due to market conditions in Mexico, Central America, and Australia.American Vanguard Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
46
Neutral
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 515.11M | 547.31M | 579.37M | 609.62M | 557.68M |
| Gross Profit | 135.44M | 120.32M | 179.16M | 241.35M | 170.72M |
| EBITDA | 25.32M | -9.43M | 44.72M | 62.79M | 57.00M |
| Net Income | -49.88M | -126.34M | 7.52M | 27.40M | 18.59M |
Balance Sheet | |||||
| Total Assets | 596.54M | 636.72M | 767.55M | 726.31M | 694.16M |
| Cash, Cash Equivalents and Short-Term Investments | 12.43M | 12.51M | 11.42M | 20.33M | 16.29M |
| Total Debt | 191.39M | 167.81M | 162.09M | 76.25M | 78.08M |
| Total Liabilities | 404.14M | 403.61M | 397.54M | 356.33M | 321.42M |
| Stockholders Equity | 192.40M | 233.11M | 370.01M | 369.98M | 372.74M |
Cash Flow | |||||
| Free Cash Flow | -3.36M | -3.77M | -70.81M | 42.55M | 76.32M |
| Operating Cash Flow | 3.92M | 3.92M | -58.75M | 57.10M | 86.36M |
| Investing Cash Flow | -6.62M | -6.62M | -17.02M | -14.47M | -20.04M |
| Financing Cash Flow | 4.54M | 4.54M | 66.74M | -38.26M | -65.87M |
American Vanguard Technical Analysis
Negative
3.79
Price Trends
4.19
Negative
4.23
Negative
4.51
Negative
Market Momentum
-0.57
Negative
27.44
Positive
55.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVD, the sentiment is Negative. The current price of 3.79 is above the 20-day moving average (MA) of 3.01, below the 50-day MA of 4.19, and below the 200-day MA of 4.51, indicating a bearish trend. The MACD of -0.57 indicates Negative momentum. The RSI at 27.44 is Positive, neither overbought nor oversold. The STOCH value of 55.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AVD.
American Vanguard Risk Analysis
American Vanguard disclosed 25 risk factors in its most recent earnings report. American Vanguard reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
American Vanguard Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $563.36M | -212.04 | 2.30% | ― | 8.88% | -349.99% | |
67 Neutral | $1.37B | 10.98 | 32.82% | 12.33% | 16.52% | 141.96% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
48 Neutral | $98.83M | -10.84 | -158.60% | ― | 45.88% | 43.12% | |
43 Neutral | $68.78M | -0.98 | -22.89% | ― | -4.29% | -276.74% | |
42 Neutral | $35.28M | -0.11 | -105.50% | ― | -27.90% | -4194.67% |
* Basic Materials Sector Average
AVD
American Vanguard
2.41
-1.27
-34.51%
UAN
CVR Partners
129.72
67.58
108.75%
IPI
Intrepid Potash
42.02
15.48
58.33%
BHST
BioHarvest Sciences
4.36
-1.04
-19.26%
BIOX
Bioceres Crop Solutions
0.56
-3.59
-86.58%
American Vanguard Corporate Events
Business Operations and StrategyPrivate Placements and Financing
American Vanguard Restructures Debt with New Term Loans
Neutral
Mar 19, 2026
On March 13, 2026, AMVAC Chemical Corporation, a subsidiary of American Vanguard, entered into new first-lien and second-lien term loan credit agreements totaling $285 million with lender groups led by Centerbridge Partners and BMO Bank. Proceeds ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.